The Hellenic Society of Cardiology organized the 42nd Panhellenic Cardiac Conference (MEGARO MUSIC OF ATHENS, October 21-23, 2021).
MedTech Conference 2021 took place for the 7th year on 21 October, this time digitally through LiveOn, under the title "Challenges in the Management of Medical Technology Products".
Virtual ISPOR Europe 2021 is the leading European conference for HEOR, bringing together global leaders for discussion and dissemination of the latest trends in healthcare. This conference is made up Virtual ISPOR Europe 2021, which will take place 30 November-3 December 2021.
The creation of Hellenic Digital Health Cluster (HDHC) was awarded in the category “National/ Regional Health Initiative” in the context of Healthcare Business Awards 2021.
Heart Vessels & Stroke 2021, a Forum of Innovations in Cardiovascular Medicine was held on September 10th-12th 2021 in Athens under the auspices of Hellenic Cardiovascular Research Society.
The Aristotle Medical Forum which represents a common meeting ground of Medical Science and Innovation with Technology, Society and Industry was held on September 9th-11th 2021.
Aligned with our strategy to evolve in the fast-changing environment, understand the needs of our clients and offer high quality customized services, we have decided to expand our capacity.
ΗealThink is very happy and proud to announce the establishment and our participation in the company "Hellenic Digital Health Cluster (HDHC)", the new dynamic initiative of the Foundation for Research and Technology (FORTH) and 20 innovative Greek companies that aspires to make Greece one of the leading countries in the field of digital health worldwide.
HTA Conference with title “The role of HTA in the era of radical changes & disruptive innovation” will be held on March 23rd 2021 (Live on our screen). After 3 years of operation of the HTA Committee and the Drug Price Negotiation Committee, we will have the chance to take a look back and reference to their difficulties, challenges and achievements as well as to assess the impact of these reforms on Greece’s pharmaceutical policy.